The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Study of the Bria-IMT regimen and CPI vs physicians' choice in advanced metastatic breast cancer (BRIA-ABC).
 
Sara A. Hurvitz
Stock and Other Ownership Interests - ROM Tech (I)
Research Funding - Ambryx (Inst); Amgen (Inst); Arvinas (Inst); AstraZeneca/Daiichi Sankyo (Inst); Bayer (Inst); Biomarin (Inst); Cascadian Therapeutics (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Dignitana (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Greenwich LifeSciences (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merrimack (Inst); Novartis (Inst); OBI Pharma (Inst); Orinove (Inst); Orum (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Pieris Pharmaceuticals (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Samumed (Inst); sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Pfizer; Roche
 
Saranya Chumsri
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Athenex; Athenex; bioTheranostics; bioTheranostics (Inst); Eisai; Immunomedics; Immunomedics; Immunomedics; Novartis; Novartis; Puma Biotechnology; Seagen; Syndax
Research Funding - Array BioPharma; Merck; Salix
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; General Electric; Gilead Sciences; Lilly; Merck; Michael J. Hennessy Associates; Myriad Pharmaceuticals; Novartis; Onc Live; Pfizer; Puma Biotechnology; Seagen
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Expert Testimony - Pfizer
 
Chaitali Singh Nangia
Consulting or Advisory Role - Gilead Sciences; Gilead Sciences; Novartis; regeneron; Sanofi; Stemline Therapeutics
Speakers' Bureau - Merck; Novartis; Regeneron; Sanofi
Travel, Accommodations, Expenses - Gilead Sciences; Novartis; Regeneron; Sanofi
 
Giuseppe Del Priore
Employment - Briacell
Leadership - Briacell
Stock and Other Ownership Interests - Briacell
 
Massimo Cristofanilli
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Celcuity; Lilly; Menarini; Olaris; Sermonix Pharmaceuticals; Syantra
Research Funding - Angle; AstraZeneca; Lilly; Menarini Silicon Biosystems; Merck